Simris Group AB, through its subsidiary Simris Biologics GmbH, has secured non-dilutive funding of €200K for the R&D program KlicMic, aimed at advancing microcystin payloads for Antibody Drug Conjugates (ADCs). This funding, jointly granted with Freie Universität Berlin under the ZIM program of the German Federal Ministry for Economic Affairs and Climate Action, will span three years starting September 1, 2025, with €201K allocated to Simris and €186K to the university.
The core objective of the KlicMic project is to pioneer novel microcystin-based payloads for ADCs, with the potential to revolutionize cancer therapy by enhancing efficacy while minimizing side effects. Simris Biologics is dedicated to developing ADCs that offer improved safety and therapeutic outcomes compared to traditional cytotoxic agents used in oncology treatments. Leveraging cyanobacteria-derived microcystins, the company presents a unique mechanism of action that holds promise for the future of targeted cancer therapies.
Through rigorous preclinical in vitro and in vivo evaluations, the optimized and labeled microcystin payloads will be tested in ADC formats before being licensed to pharmaceutical partners. This strategic approach not only highlights Simris Biologics’ commitment to innovation but also underscores its vision to drive advancements in cancer treatment, ultimately benefitting patients worldwide.
The acknowledgment extended by Simris Biologics to all project stakeholders and the funding sponsor reflects the company’s gratitude for the trust and support received. The KlicMic initiative marks a significant milestone in the pursuit of developing cancer therapies with minimal side effects, marking a pivotal advancement in the realm of targeted oncology treatments.
Simris Biologics’ unrivaled expertise in cyanobacterial toxins positions it as a key player in the evolution of the next generation of ADCs, poised to elevate the standard of care for cancer patients globally. By fostering collaborations with a diverse array of strategic partners, the company aims to expedite the development and commercialization of innovative cancer therapies that redefine treatment paradigms.
The funding approval from the German Federal Ministry for Economic Affairs and Energy, facilitated by the ZIM program, underscores the recognition of Simris Biologics’ pioneering work in advancing microcystin-based ADC payloads. This support not only validates the company’s innovative approach but also propels its mission to transform cancer treatment through cutting-edge scientific endeavors.
For further inquiries or collaborations, Dr. Alexis Roberts-McIntosh, the CEO of Simris Group AB, can be reached via email at ir@simris.com or mobile at +44 (0) 7940 585298. To stay updated on the latest developments, visit www.simrisgroup.com.
About Simris Group AB (PUBL): Simris Group is a biologics company dedicated to identifying and harnessing the therapeutic potential of natural, biologically active compounds sourced from microalgae and cyanobacteria. With a focus on applications in biopharmaceuticals, dietary supplements, and cosmetics, Simris Group is committed to driving innovation in the life sciences sector.
Simris Group’s shares are publicly traded on the Nasdaq First North Growth Market under the ticker symbol SIMRIS and ISIN code SE0008091664. The company’s Certified Adviser is Amudova AB, reachable via telephone at 08-546 017 58 or email at info@amudova.se.
Key Takeaways:
- Simris Group AB secures €200K in non-dilutive funding for the development of microcystin-based ADC payloads, marking a pivotal advancement in cancer therapy.
- The KlicMic project aims to pioneer novel ADC payloads with enhanced efficacy and reduced side effects, positioning Simris Biologics as a key player in the evolution of targeted oncology treatments.
- Leveraging its expertise in cyanobacterial toxins, Simris Biologics is poised to collaborate with strategic partners to drive the development of next-generation ADCs that elevate the standard of care for cancer patients globally.